BEIJING, June 12 /Xinhua-PRNewswire-FirstCall/ -- China Medical
Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based
medical device company that develops, manufactures and markets advanced in-
vitro diagnostic products and high intensity focused ultrasound tumor
therapy system, today announced its unaudited financial results for the
fourth quarter ("4Q FY2007") and the full year of the fiscal year ended
March 31, 2008 ("FY2007").

See "Non-GAAP Measure Disclosures" below, where the impact of certain
items on reported results ishe Company's ongoing business in a manner that
allows meaningful period-to-period comparison. The Company's management
believes that these non-GAAP financial measures provide useful information
to investors and others in understanding and evaluating the Company's
current operating performance and future prospects in the same manner as
management does, if they so choose. The Company's management also believes
the non-GAAP financial measures are useful for itself and investors because
it makes more meaningful comparisons of the Company's current results of
operations to those of prior periods.

The Company's management believes excluding the non-cash stock
compensation expense from its non-GAAP financial measures is useful for
itself and investors as such expense will not result in future cash payment
and is otherwise unrelated to the Company's core operating results.

The Company's management believes excluding the non-cash amortization
expense of acquired intangible assets resulting from acquisitions from its
non-GAAP financial measures is useful for itself and investors because they
enable a more meaningful comparison of the Company's performance between
reporting periods. In addition, such amortization will not result in cash
settlement in the future.

The presentation of this additional financial information is not
intended to be considered in isolation or as a substitute for the financial
information prepared and presented in accordance with GAAP. For a
reconciliation of the non-GAAP financial measures to the most directly
comparable GAAP financial measure, please see the financial statements
included with this press release.

Conference Call

The Company's management team will host a conference call at 8:00 a.m.
Eastern Time on June 12, 2008 (or 8:00 p.m. Beijing/Hong Kong time on the
same date) to discuss the results following this earnings announcement.

A replay of this webcast will be available for one month on this
website.

A telephone replay of the call will be available after the conclusion
of the conference call through 10:00 a.m. Eastern Time on June 13, 2008.

The dial-in details for the replay are as follows:

-- U.S. Toll Free Number 1-888-286-8010

-- International dial-in numbers 1-617-801-6888

Passcode 52979476

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device
company that develops, manufactures and markets advanced in-vitro
diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and
Fluorescent in situ Hybridization (FISH) technology, to detect and monitor
various diseases and disorders, and system using High Intensity Focused
Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For
more information, please visit http://www.chinameditech.com .

Safe Harbor Statement

This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as "will," "expects,"
"anticipates," "future," "intends," "plans," "believes," "estimates" and
similar statements. Among other things, the quotations from management in
this press release, the Company's strategic operational plans, as well as
outlook for FY2008, contain forward-looking statements. Such statements
involve certain risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements. Further
information regarding these and other risks is included in the Company's
filings with the U.S. Securities and Exchange Commission, including its
annual report on Form 20-F. The Company does not undertake any obligation
to update any forward-looking statement as a result of new information,
future events or otherwise, except as required under applicable law.

China Medical Technologies, Inc.

Unaudited Condensed Consolidated Balance Sheets

As of

March 31, December

2007 31, 2007 March 31, 2008

RMB RMB RMB US$

(in thousands)

Assets

Current assets

Cash and cash equivalents 1,173,640 950,311 682,679 97,359

Trade accounts receivable 201,778 253,186 289,751 41,322

Prepayments and other

receivables 41,484 38,123 27,845 3,971

Inventories 27,991 31,858 27,834 3,969

Total current assets 1,444,893 1,273,478 1,028,109 146,621

Property, plant and

equipment, net 135,792 152,027 164,499 23,460

Land use rights 7,619 7,478 7,430 1,060

Goodwill -- -- 8,654 1,234

Intangible assets, net 1,565,362 1,425,519 1,541,793 219,879

Prepayments and other

receivables -- 298,605 154,264 22,000

Convertible notes

issuance costs 38,020 30,086 27,055 3,858

Deferred income taxes 542 -- -- --

Total assets 3,192,228 3,187,193 2,931,804 418,112

Liabilities

Current liabilities

Trade accounts payable 47,847 47,739 48,040 6,851

Accrued liabilities

and other payables 594,489 503,200 238,580 34,025

Income taxes 38,467 51,152 69,499 9,911

Total current

liabilities 680,803 602,091 356,119 50,787

Convertible notes 1,158,480 1,094,190 1,051,800 150,000

Other payable - long term 67,206 67,265 -- --

Deferred income taxes -- 202 1,124 160

Total liabilities 1,906,489 1,763,748 1,409,043 200,947

Shareholders' equity

Ordinary shares US$0.1

par value: 500,000,000

authorized; 273,600,001

issued and outstanding as

of March 31, 2007,

274,066,661 issued and

outstanding as of

December 31, 2007 and

March 31, 2008 225,125 225,473 225,473 32,155

Additional paid-in

capital 504,795 521,596 526,264 75,052

Accumulated other

comprehensive loss (21,335) (37,481) (48,046) (6,852)

Retained earnings 577,154 713,857 819,070 116,810

Total shareholders'

equity 1,285,739 1,423,445 1,522,761 217,165

Total liabilities

and shareholders'

equity 3,192,228 3,187,193 2,931,804 418,112

Note:

The Company has performed preliminary purchase price allocation after
completion of acquisition in Beijing Bio-Ekon Biotechnology Co., Ltd. in
January 2008. The Company will finalize the purchase price allocation as
soon as practicable.

China Medical Technologies, Inc.

Unaudited Condensed Consolidated Statements of Income

For the Three Months Ended

March 31, December 31,

2007 2007 March 31, 2008

RMB RMB RMB US$

(in thousands except for per ADS information)

Revenues (1) 163,103 265,133 284,219 40,533

Cost of revenues (43,766) (97,643) (101,742) (14,510)

Gross profit 119,337 167,490 182,477 26,023

Operating expenses:

Research and

development (7,960) (11,577) (11,423) (1,629)

Sales and marketing (5,395) (8,490) (8,236) (1,175)

General and

administrative (18,259) (24,154) (16,347) (2,331)

Total operating

expenses (31,614) (44,221) (36,006) (5,135)

Operating income 87,723 123,269 146,471 20,888

Other income 2,300 3,033 -- --

Interest income 15,143 7,136 5,034 718

Interest expense -

convertible notes (10,183) (9,755) (9,396) (1,340)

Interest expense -

amortization of

convertible notes

issuance cost (2,064) (1,978) (1,905) (272)

Interest expense -

other -- (1,181) (1,299) (185)

Income before income

tax 92,919 120,524 138,905 19,809

Income tax expense (9,194) (22,723) (33,692) (4,805)

Net income 83,725 97,801 105,213 15,004

Earnings per ADS

- basic 3.20 3.73 4.01 0.57

- diluted (2) 3.11 3.52 3.74 0.53

Weighted average

number of ADS

- basic 26,196,308 26,238,264 26,242,974 26,242,974

- diluted (2) 30,882,901 31,080,129 31,116,665 31,116,665

Notes:

(1) Revenues

- ECLIA 65,879 96,663 112,221 16,004

- FISH -- 52,831 68,827 9,816

- HIFU 97,224 115,639 103,171 14,713

163,103 265,133 284,219 40,533

For the Years Ended

March 31,

2007 March 31, 2008

RMB RMB US$

(in thousands except for per ADS information)

Revenues (1) 546,970 915,738 130,596

Cost of revenues (151,614) (346,436) (49,406)

Gross profit 395,356 569,302 81,190

Operating expenses:

Research and development (31,469) (40,875) (5,829)

Sales and marketing (18,264) (29,099) (4,150)

General and administrative (55,352) (75,376) (10,750)

Total operating expenses (105,085) (145,350) (20,729)

Operating income 290,271 423,952 60,461

Other income 6,024 3,133 447

Interest income 41,970 28,649 4,086

Interest expense - convertible notes (15,342) (39,149) (5,583)

Interest expense - amortization of

convertible notes issuance cost (3,111) (7,937) (1,132)

Interest expense - other -- (5,229) (746)

Income before income tax 319,812 403,419 57,533

Income tax expense (30,094) (78,197) (11,152)

Net income 289,718 325,222 46,381

Earnings per ADS - basic 10.76 12.40 1.77

- diluted (2) 10.74 11.99 1.71

Weighted average number of ADS 26,923,217 26,221,900 26,221,900

- basic

- diluted (2) 28,697,979 31,039,668 31,039,668

Notes:

(1) Revenues

- ECLIA 215,550 380,520 54,267

- FISH -- 166,901 23,802

- HIFU 331,420 368,317 52,527

546,970 915,738 130,596

Notes:

(2) In computing diluted earnings per ADS for the three months and full
year of the fiscal year ended March 31, 2008, interest expense and
amortization in connection with convertible notes were added back to net
income before dividing net income by the diluted number of ADS, which
included shares that may be issued from the conversion of convertible
notes.

China Medical Technologies, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

For the Years Ended

March 31,

2007 March 31, 2008

RMB RMB US$

(in thousands)

Net cash provided by

operating activities 360,999 463,334 66,077

Net cash used in investing

activities (884,455) (831,551) (118,589)

Net cash provided by (used

in) financing activities 871,554 (86,149) (12,286)

Effect of foreign currency

exchange rate change on cash (18,249) (36,595) (5,219)

Net increase (decrease) in

cash and cash equivalents 329,849 (490,961) (70,017)

Cash and cash equivalents:

At beginning of year 843,791 1,173,640 167,376

At end of year 1,173,640 682,679 97,359

China Medical Technologies, Inc.

Reconciliations of Non-GAAP Adjusted Net Income to GAAP Net Income

For the Three Months Ended

March 31, December 31,

2007 2007 March 31, 2008

RMB RMB RMB US$

(in thousands except for per ADS information)

GAAP net income 83,725 97,801 105,213 15,004

Adjustments:

Stock compensation

expense 311 5,074 4,669 666

Amortization of

acquired intangible

assets 7,747 21,876 23,700 3,380

Non-GAAP adjusted

net income 91,783 124,751 133,582 19,050

GAAP earnings per

ADS

- basic 3.20 3.73 4.01 0.57

- diluted 3.11 3.52 3.74 0.53

Non-GAAP adjusted

earnings per ADS

- basic 3.50 4.75 5.10 0.73

- diluted 3.37 4.39 4.66 0.66

Weighted average

number of ADS

- basic 26,196,308 26,238,264 26,242,974 26,242,974

- diluted 30,882,901 31,080,129 31,116,665 31,116,665

For the Years Ended

March 31,

2007 March 31, 2008

RMB RMB US$

(in thousands except for per ADS information)

GAAP net income 289,719 325,222 46,381

Adjustments:

Stock compensation expense 1,278 16,660 2,376

Amortization of acquired intangible

assets 18,935 90,233 12,868

Non-GAAP adjusted net income 309,932 432,115 61,625

GAAP earnings per ADS

- basic 10.76 12.40 1.77

- diluted 10.74 11.99 1.71

Non-GAAP adjusted earnings per ADS

- basic 11.51 16.48 2.35

- diluted 11.44 15.44 2.20

Weighted average number of ADS

- basic 26,923,217 26,221,900 26,221,900

- diluted 28,697,979 31,039,668 31,039,668

Note:

(1) In computing diluted GAAP and non-GAAP earnings per ADS for the
three months ended and full year of the fiscal year ended March 31, 2008,
interest expense and amortization in connection with convertible notes were
added back to GAAP and non-GAAP net income, respectively, before dividing
the GAAP and non-GAAP net income by the diluted number of ADS, which
included shares that may be issued from the conversion of convertible
notes.

"FY2007 was a landmark year for China Medical Technologies to become an
advanced IVD company," commented Mr. Xiaodong Wu, Chairman and CEO of the
Company. "About 60% of our revenues were generated from both ECLIA and FISH
diagnostic businesses. We expect a higher percentage of our revenues to be
generated from these businesses in FY2008 as our recurring reagent sales
continue to grow rapidly. We successfully launched our FISH business in
FY2007 and have established a direct sales network of selling our FISH
reagents to more than 200 large hospitals in China. We will expand the
direct sales network to cover more than 500 large hospitals in China by the
end of FY2008. We believe that this network will help the Company maintain
a close relationship with a large group of high end hospital consumers in
China and benefit the Company by selling all its products to these
hospitals in the long term."

"We faced challenges upon the launch of our new diagnostic FISH
business and transportation interruption in southern China by the heavy
snow storm during FY2007. We also faced several interest rate reductions
which decreased our interest income as well as the delay in the assessment
of hi-tech enterprise designation for Chinese companies by the PRC
government which increased our income tax expense," commented Mr. Sam
Tsang, CFO of the Company. "Despite these challenges, we managed to exceed
our targeted revenues and adjusted net income which we revised upward in
November 2007. These were the results of our successful execution of our
strategies for FISH business and timely reaction to business interruption
caused by natural disaster. Again, we challenge ourselves by setting new
targeted revenues and adjusted net income for FY2008 which are detailed
under "Outlook for FY2008" below. Besides, I have tried to compare our
results and new targets to Thomson First Call mean which is commonly
referred to by our shareholders and investors but found that there are only
two sell-side analysts covering the Company. I believe it is not in the
best interest of our shareholders and potential investors and have included
the task of increasing sell-side analyst coverage to my task list for
FY2008."

4Q FY2007 Financial Results

The Company reported revenues of RMB284.2 million (US$40.5 million) for
4Q FY2007, representing a 74.3% increase from the corresponding period of
FY2006.

The Company's revenues are currently generated from three product
lines, ECLIA diagnostic systems, FISH diagnostic systems and HIFU tumor
therapy systems. ECLIA and FISH system sales include the sales of equipment
and reagent kits.

ECLIA system revenues for 4Q FY2007 were RMB112.2 million (US$16.0
million), representing a 70.3% increase from the corresponding period of
FY2006. The strong year-over-year growth in the ECLIA system revenues
reflected the increasing utilization of ECLIA equipment by hospitals and
the introduction of new reagents, both of which drove increasing demand for
reagent kits.

FISH system revenues for 4Q FY2007 were RMB68.8 million (US$9.8
million). We launched our FISH systems in 1Q FY2007.

HIFU tumor therapy system revenues for 4Q FY2007 were RMB103.2 million
(US$14.7 million), representing a 6.1% increase from the corresponding
period of FY2006. The year-over-year growth in this sector was driven
primarily by increases in unit sales.

Gross margin decreased to 64.2% for 4Q FY2007 as compared to 73.2% for
the corresponding period of FY2006. The decrease in gross margin was mainly
due to the amortization of FISH intangible assets of RMB17.5 million
(US$2.5 million) which resulted in a 6.2% decrease in gross margin. In
addition, FISH equipment sales generated lower gross margin. However, FISH
reagent sales generate recurring revenue and higher gross margin for the
Company. The rapid growth in FISH reagent sales will improve the gross
margin in the future.

Research and development expenses were RMB11.4 million (US$1.6 million)
for 4Q FY2007, representing a 43.5% year-over-year increase. The increase
was primarily due to the development of new ECLIA and FISH reagents.

Sales and marketing expenses were RMB8.2 million (US$1.2 million) for
4Q FY2007, representing a 52.7% year-over-year increase. The increase was
primarily due to the establishment and expansion of direct sales force and
promotional activities for FISH systems.

General and administrative expenses were RMB16.3 million (US$2.3
million) for 4Q FY2007, representing a 10.5% year-over-year decrease. The
decrease was primarily due to the decrease in cash bonus for senior
management.

Interest income was RMB5.0 million (US$0.7 million) for 4Q FY2007,
representing a 66.8% decrease from the corresponding period of FY2006. The
decrease was primarily due to lower cash balance as a result of payments
made for the FISH and other acquisitions and a decrease in the interest
rate for US dollar bank deposits.

Interest expense of convertible notes was RMB9.4 million (US$1.3
million) for 4Q FY2007. The notes bear interest at 3.5% per annum.

Other interest expense of RMB1.3 million (US$0.2 million) for 4Q FY2007
was primarily due to the present value discounting of long term other
payable of US$10 million for the final payment of FISH acquisition due in
March 2009.

Income tax expense was RMB33.7 million (US$4.8 million) for 4Q FY2007.
The effective tax rate for 4Q FY2007 was 24.3% primarily due to the
increase in income tax rate from 10% to the transitional rate of 18% in
connection with the New Law effective in January 2008 as well as certain
non-deductible expenses for income tax.

The China Unified Corporate Income Tax Law (the "New Law") became
effective on January 1, 2008. The New Law established a single unified 25%
income tax rate for most companies with some preferential income tax rates
including 15% income tax rate to be applicable to qualified hi-tech
enterprises. The related detailed implementation rules and regulations on
the definition of various terms and the interpretation and application of
the provisions of the New Law were promulgated by the State Council in
December 2007 and April 2008. However, the application for hi-tech
enterprise under the New Law is pending for the implementation by the
relevant government authorities. Before the approval of hi-tech enterprise,
the Company is required to pay income tax in accordance with the
transitional income tax arrangement where the income tax rate is 18% in
2008 and 20% in 2009. The Company believes that it meets the criteria of
hi-tech enterprise under the New Law and is ready to make the application
when the government authorities commence the process.

Net income was RMB105.2 million (US$15.0 million) for 4Q FY2007,
representing a 25.7% increase from the corresponding period of FY2006.

Adjusted net income excluding stock compensation expense and
amortization of acquired intangible assets (non-GAAP) was RMB133.6 million
(US$19.1 million) for 4Q FY2007, representing a 45.5% increase from the
corresponding period of FY2006. The lower growth rate compared to net
revenues was primarily due to convertible note expenses of RMB11.3 million
(US$1.6 million), a decrease in interest income and an increase in
effective income tax rate.

Stock compensation expense for 4Q FY2007 was RMB4.7 million (US$0.7
million), which was allocated to research and development expenses (RMB1.7
million) and general and administrative expenses (RMB3.0 million),
respectively.

Amortization of acquired intangible assets for 4Q FY2007 was RMB23.7
million (US$3.4 million), which was allocated to cost of revenues.

As of March 31, 2008, the Company's cash balance was RMB682.7 million
(US$97.4 million).

As of March 31, 2008, the Company's accounts receivable was RMB289.8
million (US$41.3 million), representing an increase of 14.4% from the
balance at December 31, 2007. Accounts receivable turnover days were 114
days in this quarter compared to 115 days in previous quarter.

FY2007 Financial Results

Revenues were RMB915.7 million (US$130.6 million) for FY2007,
representing a 67.4% year-over-year increase. The targeted revenues for
FY2007 ranged from RMB860 million to RMB885 million which were revised
upward in November 2007.

ECLIA system revenues for FY2007 were RMB380.5 million (US$54.3
million), representing a 76.5% year-over-year increase. FISH system
revenues for FY2007 were RMB166.9 million (US$23.8 million) after the
launch of our FISH systems in 1Q FY2007. HIFU tumor therapy system revenues
for FY2007 were RMB368.3 million (US$52.5 million), representing a 11.1%
year-over-year increase.

Gross margin decreased to 62.2% for FY2007 as compared to 72.3% for
FY2006 primarily due to similar reasons for 4Q FY2007. During FY2007,
quarterly gross margin showed improvement in 3Q FY2007 and 4Q FY2007 which
were 63.2% and 64.2% respectively primarily due to increasing sales of FISH
reagents.

Research and development expenses were RMB40.9 million (US$5.8 million)
for FY2007, representing a 29.9% year-over-year increase. The increase was
primarily due to the development of new ECLIA and FISH reagents.

Sales and marketing expenses were RMB29.1 million (US$4.2 million) for
FY2007, representing a 59.3% year-over-year increase. This increase was
primarily due to the establishment and expansion of direct sales force for
FISH systems and promotional activities for both ECLIA and FISH systems.

General and administrative expenses were RMB75.4 million (US$10.8
million) for FY2007, representing a 36.2% year-over-year increase primarily
due to an increase in headcount to meet the expansion of the Company's
operations and stock compensation expense arising from the grant of
restricted stock and stock options in June 2007.

Other income was RMB3.1 million (US$0.4 million) for FY2007, which was
primarily due to government grants.

Interest income was RMB28.6 million (US$4.1 million) for FY2007,
representing a 31.7% year-over-year decrease. The decrease was primarily
due to lower cash balance as a result of payments made for the FISH and
other acquisitions and a decrease in interest rate for US dollar bank
deposits.

Interest expense of convertible notes was RMB39.1 million (US$5.6
million) for FY2007. The notes bear interest at 3.5% per annum and were
issued in November 2006.

Interest expense of amortization of convertible notes issuance cost was
RMB7.9 million (US$1.1 million) for FY2007.

Other interest expense of RMB5.2 million (US$0.7 million) for FY2007
was due to the present value discounting of long term other payable of
US$10 million for the final payment of FISH acquisition due in March 2009.

Income tax expense was RMB78.2 million (US$11.2 million) for FY2007.
The effective tax rate for FY2007 was 19.4% primarily due to the increase
in income tax rate from 10% to the transitional rate of 18% in connection
with the New Law effective in January 2008 as well as certain
non-deductible expenses for income tax.

Net income was RMB325.2 million (US$46.4 million) for FY2007,
representing a 12.3% year-over-year increase.

Adjusted net income excluding stock compensation expense and
amortization of acquired intangible assets (non-GAAP) was RMB432.1 million
(US$61.6 million) for FY2007, representing a 39.4% year-over-year increase.
The targeted adjusted net income for FY2007 ranged from RMB410 million to
RMB420 million which were revised upward in November 2007.

Stock compensation expense for FY2007 was RMB16.7 million (US$2.4
million), which was allocated to research and development expenses (RMB2.8
million) and general and administrative expenses (RMB13.9 million),
respectively. The Company approved the grant of 3,560,000 restricted stock,
equivalent to 356,000 ADS to certain directors, officers and employees on
June 6, 2008 which was approximately 1.3% of the issued shares. The
restricted stock vests over a period of three years.

Amortization of acquired intangible assets for FY2007 was RMB90.2
million (US$12.9 million), which was allocated to cost of revenues.

For the convenience of readers, certain RMB amounts have been
translated into U.S. dollars at the rate of RMB7.012 to US$1.00, the noon
buying rate in New York City for cable transfers of RMB per U.S. dollar as
certified for customs purposes by the Federal Reserve Bank of New York, as
of Monday, March 31, 2008.

Cash Dividend

The Board of Directors has declared a cash dividend on its ordinary
shares of US$0.05 per share, equivalent to US$0.5 per ADS based on the
Company's net income for FY2007. The cash dividend will be paid on or
around August 28, 2008 to shareholders of record as of July 25, 2008.

Outlook for FY2008

The Company's reagent businesses from both ECLIA and FISH systems will
drive the growth of the Company for FY2008 despite the decline in equipment
sales of the two systems. The Company has introduced the reagent rental
arrangement for our ECLIA system so that qualified hospitals can use the
Company's ECLIA equipment free of charge but have to purchase the Company's
ECLIA reagents. The Company expects the arrangement to expand the
penetration of its ECLIA equipment to more hospitals especially high end
and low end hospitals. Regarding FISH system, the Company does not
manufacture the microscopes used for observing the results of FISH tests.
The Company purchases the microscopes and sells them to hospitals.
Recently, the Company has referred the hospitals to purchase the
microscopes directly from the manufacturers so that hospitals can reduce
the cost of setting up this new diagnostic platform and expedite the
commencement of this diagnostic service to patients. As a result, more
hospitals will use the Company's FISH reagents faster and drive the growth
of the FISH reagent revenue. Both ECLIA and FISH reagent sales are
recurring in nature and generate high gross margin for the Company.

The targeted net revenues for the fiscal year ending March 31, 2009 are
expected to be between RMB1,190 million (US$169.7 million) and RMB1,230
million (US$175.4 million), representing a year-over-year increase of 30.0%
- 34.3%.

The targeted adjusted net income excluding stock compensation expense
and amortization of acquired intangible assets (non-GAAP) for the fiscal
year ending March 31, 2009 are expected to be between RMB585 million
(US$83.4 million) and RMB605 million (US$86.3 million), representing a
year-over-year increase of 35.4% - 40.0%.

The targeted adjusted diluted EPS excluding stock compensation expense
and amortization of acquired intangible assets (non-GAAP) for the fiscal
year ending March 31, 2009 is expected to be between RMB20.10 (US$2.87) and
RMB20.73 (US$2.96) assuming a diluted number of ADS of about 31.5 million
and excluding interest for convertible notes and amortization of
convertible notes issuance cost, representing a year-over-year increase of
30.1% - 34.3%.

The above targets are based on the Company's current views on the
operating and marketing conditions which are subject to change.

Non-GAAP Measure Disclosures

To supplement its consolidated financial statements presented in
accordance with United States Generally Accepted Accounting Principles
("GAAP"), the Company uses non-GAAP measures of adjusted net income and
adjusted earnings per ADS, which are adjusted from results based on GAAP to
exclude the impact of stock compensation expense and amortization of
acquired intangible assets. Non-GAAP financial measures are used by the
Company in their financial and operating decision-making because management
believes they reflect t'/>"/>

(Date:12/8/2016)... ... December 08, 2016 , ... ... (WCRI) officially opened registration today for its 33rd Annual Issues & Research ... . , The theme of the conference is “Persistent Challenges and New Opportunities: ...

(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...

(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...

(Date:12/8/2016)... ... December 08, 2016 , ... The Dan ... headquartered in Jefferson County, is announcing the launch of a charity drive to ... number of homeless women and children in Birmingham has grown steadily since the ...

(Date:12/8/2016)... -- Australia Ophthalmic Lasers Market Outlook to 2022 ... Outlook to 2022", provides key market data on the ... millions of US dollars, volume (in units) and average ... Lasers and YAG Lasers. The report also provides ... these market segements, and global corporate-level profiles of the ...

(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...

(Date:12/8/2016)... Dec 8, 2016 Research and Markets has announced the ... to their offering. ... This report analyzes the worldwide markets for Endodontic Supplies in ... Canada , Japan , Europe , ... of World. Annual estimates and forecasts are provided for the period ...